The multiple myeloma therapeutic landscape has undergone a significant transformation with the FDA’s approval of Johnson & Johnson (NYSE:JNJ)’s DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the treatment of adult patients with high-risk smoldering multiple myeloma (HR-SMM). This regulatory milestone, announced on November 6, 2025, represents a significant moment in oncology, positioning disease-modifying intervention at an earlier, asymptomatic disease state and fundamentally reshaping the treatment paradigm for a patient population historically managed through active surveillance and watchful waiting.

For more detailed market analysis, epidemiological insights, and unmet needs on the Multiple Myeloma landscape, download DelveInsight’s comprehensive “Multiple Myeloma Market Insights, Epidemiology and Market Forecast” report

Clinical Excellence Drives DARZALEX FASPRO FDA Approval

The FDA’s approval decision was informed by compelling efficacy data from the Phase 3 AQUILA trial (NCT03301220), which evaluated daratumumab and hyaluronidase-fihj monotherapy versus active monitoring in 390 patients with high-risk smoldering multiple myeloma, the largest Phase 3 pivotal trial conducted in this disease state. The trial demonstrated a remarkable 51 percent reduction in the risk of progression to active multiple myeloma or death compared to active monitoring, achieving statistical significance (Hazard Ratio: 0.49; 95% CI: 0.36-0.67; p <0.0001).

At a median follow-up of 65.2 months, progression-free survival data revealed that 63.1 percent of patients receiving DARZALEX FASPRO had not progressed to active myeloma at 5 years compared to 40.7 percent in the active monitoring arm. This substantial differential underscores the transformative clinical potential of early therapeutic intervention in this disease population. In a post hoc analysis utilizing the Mayo 2018 criteria (20/2/20) to assess high-risk status, median progression-free survival was not reached in the DARZALEX FASPRO arm and was 22.1 months in the active monitoring arm (HR: 0.36; 95% CI: 0.23-0.58), further substantiating benefit in the highest-risk patient subpopulation.

Beyond the primary progression-free survival endpoint, secondary efficacy measures demonstrated robust clinical activity. Overall response rate was 63.4 percent with DARZALEX FASPRO compared to 2.0 percent with active monitoring (p <0.001). The median time to initiation of first-line multiple myeloma treatment was substantially delayed in the active drug arm compared to the observation cohort (not reached versus 50.2 months; HR: 0.46; 95% CI: 0.33-0.62), reducing cumulative therapeutic burden and delaying exposure to additional cytotoxic and immunomodulatory agents.

Addressing the High-Risk Smoldering Multiple Myeloma Unmet Medical Need

High-risk smoldering multiple myeloma represents a critically underserved disease segment within hematologic malignancies. This asymptomatic precursor condition, characterized by clonal bone marrow infiltration and measurable disease parameters in the absence of end-organ damage or myeloma defining events, places patients at substantial short-term risk for progression to symptomatic, treatment-requiring active multiple myeloma.

The epidemiological burden of Smoldering Multiple Myeloma in developed markets is considerable. In the United States, approximately 15 percent of all multiple myeloma diagnoses are classified as smoldering myeloma, with an estimated 50 percent of patients with high-risk disease progressing to active myeloma within two years of diagnosis. This compressed progression timeline creates an urgent clinical imperative for earlier therapeutic intervention in high-risk disease states. Prior to the DARZALEX FASPRO approval, the standard of care for high-risk SMM consisted of active monitoring—a strategy of sequential laboratory assessments and imaging to detect biochemical progression and end-organ damage, with deferred treatment initiation pending evidence of active disease manifestations.

According to DelveInsight’s comprehensive multiple myeloma market research, the High-Risk Smoldering Multiple Myeloma disease state has historically remained underdiagnosed and undertreated, despite the substantial disease burden and high progression rates. The approval of DARZALEX FASPRO as the first and only therapy for this indication establishes a new treatment standard grounded in precision disease-staging and early intervention, fundamentally altering clinical decision-making and patient management strategies across the myeloma care continuum.

DARZALEX FASPRO Mechanism of Action and Therapeutic Rationale

DARZALEX FASPRO comprises daratumumab, a humanized IgG kappa monoclonal antibody targeting CD38, a surface antigen highly expressed on multiple myeloma cells, combined with recombinant human hyaluronidase PH20 (rHuPH20; Halozyme’s ENHANZE drug delivery technology). The subcutaneous formulation enables patient self-administration and improved dosing convenience compared to intravenous alternatives.

Daratumumab’s mechanism of action in multiple myeloma is multifaceted, involving direct targeting and depletion of CD38-expressing malignant plasma cells through antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis, and complement-dependent cytotoxicity. In the high-risk smoldering setting, daratumumab monotherapy achieves disease suppression and delays progression to active disease, positioning early intervention as a strategy to interrupt the malignant transformation cascade and extend the asymptomatic disease phase.

The subcutaneous FASPRO formulation demonstrates enhanced pharmacokinetic properties and patient convenience compared to the intravenous DARZALEX formulation. Fixed-duration treatment lasting up to 36 months or until disease progression or unacceptable toxicity further distinguishes this therapeutic approach, providing defined treatment horizons and enabling structured clinical surveillance protocols.

DARZALEX FASPRO Safety Profile and Clinical Tolerability

The safety profile of DARZALEX FASPRO monotherapy in high-risk smoldering myeloma was consistent with prior safety data from relapsed or refractory disease populations. The most common adverse reactions (≥20%) among HR-SMM patients included upper respiratory tract infection, musculoskeletal pain, fatigue, diarrhea, rash, sleep disorder, sensory neuropathy, and injection site reactions. System administration-related reactions occurred in 17 percent of patients in the AQUILA cohort (Grade 2: 7%; Grade 3: 1%), with injection-site reactions reported in 28 percent of patients (Grade 2: 3%).

Serious infections, including opportunistic infections, occurred in 24 percent of pooled safety population patients receiving DARZALEX FASPRO, with Grade 3-4 infections in 22 percent and fatal infections in 2.5 percent. Neutropenia and thrombocytopenia were observed and may be exacerbated in patients with underlying bone marrow reserve limitations. The prescribing information includes warnings and precautions for hypersensitivity reactions, infections, neutropenia, thrombocytopenia, embryo-fetal toxicity, and interference with serological cross-matching.

Notably, the favorable tolerability profile and low treatment discontinuation rates attributable to adverse effects underscore the clinical manageability of DARZALEX FASPRO monotherapy in the high-risk SMM population, supporting its integration into early treatment strategies.

Multiple Myeloma Competitive Landscape and Market Implications

The DARZALEX FASPRO approval as monotherapy for high-risk Smoldering Multiple Myeloma establishes a differentiated therapeutic positioning within the evolving multiple myeloma treatment ecosystem. The multiple myeloma market, valued at billions of dollars globally, continues to experience therapeutic innovation across multiple disease stages, with growing emphasis on early intervention and disease prevention strategies.

According to DelveInsight’s multiple myeloma market intelligence, the High-Risk Smoldering Multiple Myeloma disease segment represents an emerging therapeutic opportunity characterized by substantial patient populations, limited treatment options prior to this approval, and significant unmet clinical need. The market is expected to experience expansion driven by improved diagnostic methodologies, increased disease awareness among hematology practitioners, and validated therapeutic strategies demonstrating disease modification in earlier disease stages.

DARZALEX FASPRO’s first-mover advantage in establishing a disease-modifying therapy for high-risk SMM positions Janssen favorably within the competitive landscape. However, the expanding pipeline of multiple myeloma therapeutics in development, including novel immunomodulatory agents, proteasome inhibitors, monoclonal antibodies targeting distinct epitopes, and bi-specific T-cell engagers, ensures continued competitive intensity and innovation acceleration within the disease category.

Healthcare System Integration and Clinical Practice Implications

The integration of DARZALEX FASPRO into clinical hematology practice necessitates substantial healthcare infrastructure development, including patient identification and risk-stratification protocols, multidisciplinary care coordination, and specialized monitoring frameworks. Early identification of high-risk SMM patients requires systematic application of validated risk criteria, including the Mayo 2018 high-risk criteria (serum monoclonal protein >2 g/dL, involved-to-uninvolved serum-free light chain ratio >20, and bone marrow plasma cells >20%), combined with cytogenetic risk assessment.

Healthcare providers implementing DARZALEX FASPRO therapy should establish clear treatment initiation criteria, informed consent processes addressing disease modification versus observation strategies, and long-term surveillance protocols monitoring progression-free survival and overall survival outcomes. Patient education initiatives should emphasize subcutaneous administration techniques, infection prevention strategies, and recognition of administration-related reactions requiring immediate medical evaluation.

Regulatory Pathway and Future Evidence Requirements

The FDA approval of DARZALEX FASPRO for high-risk Smoldering Multiple Myeloma follows a rigorous regulatory process including a May 2025 favorable vote by the FDA Oncologic Drugs Advisory Committee, substantiating the benefit-risk profile supporting early disease intervention. This approval adds the high-risk SMM indication to DARZALEX FASPRO’s existing portfolio of ten multiple myeloma indications, four of which address frontline newly diagnosed disease in transplant-eligible and ineligible populations.

Janssen remains committed to clinical evidence generation supporting DARZALEX FASPRO’s role within the myeloma treatment continuum. Ongoing AQUILA trial data collection includes assessment of secondary endpoints including annualized slope of estimated glomerular filtration rate decline over 24 months, anticipated for early 2026. Additional subgroup analyses evaluating efficacy and safety stratified by baseline prognostic factors are expected to facilitate precision treatment selection and patient risk-benefit optimization.

DARZALEX FASPRO FDA Approval: Strategic Implications and Future Outlook

For the pharmaceutical industry, the DARZALEX FASPRO approval in high-risk SMM validates early intervention strategies in asymptomatic disease states and may catalyze investment prioritization in disease-modifying therapies targeting precursor malignancies. Competitive organizations with myeloma pipeline programs should anticipate accelerated regulatory timelines and enhanced clinical trial design sophistication in early disease stages.

For hematology practice, the therapeutic landscape increasingly emphasizes disease staging precision, prognostic stratification, and risk-adapted treatment strategies. The transition from observation-only management of high-risk SMM to active disease modification represents a paradigm shift with implications for patient outcomes, healthcare economics, and quality-of-life considerations across the treatment continuum.

For patients diagnosed with high-risk smoldering multiple myeloma, the DARZALEX FASPRO approval offers unprecedented therapeutic options enabling disease modification and progression delay prior to development of symptomatic active disease. The subcutaneous, fixed-duration treatment regimen provides improved convenience and reduced cumulative therapeutic burden compared to potential sequential active myeloma treatment approaches.

Conclusion

The FDA approval of DARZALEX FASPRO for high-risk smoldering multiple myeloma represents a landmark achievement in early cancer intervention, establishing a new therapeutic standard for asymptomatic disease with substantial progression risk. As the first and only approved therapy for this indication, DARZALEX FASPRO addresses a critical unmet medical need while establishing precision disease-modifying intervention as a foundational strategy within the evolving myeloma treatment paradigm.

The transition from observation-only management of high-risk SMM to active disease modification represents a transformative evolution in hematologic malignancy care, grounded in mechanistic understanding of disease progression and supported by robust clinical evidence. As the multiple myeloma pharmaceutical landscape continues evolving with advancing pipeline candidates and expanding therapeutic options across disease stages, DARZALEX FASPRO’s role in early disease interception establishes a precedent for future innovation in malignancy prevention and disease control.

DelveInsight continues to monitor competitive developments in multiple myeloma therapeutics, market dynamics, and clinical evidence generation supporting precision treatment strategies across disease stages. For comprehensive competitive intelligence, market analysis, and strategic insights regarding multiple myeloma treatment evolution and market opportunities, DelveInsight’s multiple myeloma market research reports provide evidence-based analysis and industry benchmarking supporting informed business decision-making.